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A B S T R A C TObjectives: Based on qualitative research of patients with chronic
obstructive pulmonary disease (COPD), the Shortness of Breath (SOB)
with Daily Activities (SOBDA) questionnaire was developed as a
patient-reported outcome instrument to evaluate the impact of
therapy on SOB and assess how SOB affects daily activities. Methods:
Development of the SOBDA questionnaire consisted of three compo-
nents. First, focus groups of patients with COPD were asked to
describe their experiences of SOB with daily activities. A pool of items
was drafted on the basis of information from the focus groups and
literature reviews, and then discussed among instrument develop-
ment and clinical experts. Cognitive debriefing interviews of patients
were conducted to assess the draft item pool, and their feedback was
used to develop newer versions of the questionnaire. Input was also
sought from the Food and Drug Administration, patients, and clin-
icians. Results: Forty patients participated in seven focus groups. The
terms most often used to describe SOB were ‘‘short of breath’’ ornt matter Copyright & 2012, International Society
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.1016/j.jval.2012.06.018
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ndence to: Teresa K Wilcox, United BioSource Corpo‘‘difficulty breathing.’’ Patients were clearly able to distinguish SOB
from chest congestion and wheezing, other common symptoms
associated with COPD. The resulting item pool contained 37 items to
assess SOB associated with everyday activities, and concept saturation
was reached. Thirty-seven patients participated in the subsequent
cognitive debriefing interviews. Patients found the items clear and
easy to understand with relevance to their everyday experiences, and
easy to use in an electronic format. Conclusions: Instructions and
response options to the SOBDA questionnaire were well understood by
patients with COPD, and item relevance was confirmed. Prospective
validation and item reduction studies are highly anticipated.
Keywords: COPD, patient-reported outcomes, qualitative research,
quality of life.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and
treatable disease characterized by progressive airflow limitation
that is not fully reversible [1]. It is associated with an abnormal
inflammatory response in the lung to noxious particles or gases.
The principal marker for the physiologic changes in airflow
limitation, which is characteristic of the disease, is lung function,
measured as forced expiratory volume in 1 second (FEV1). This
marker correlates poorly with the severity of dyspnea (usually
described by patients as shortness of breath [SOB]) and other
symptoms of COPD [1,2]. Therefore, changes in FEV1 may not always
reflect symptomatic changes that are clinically meaningful for
patients. Avariety of biologic, physiologic, and symptomatic markers
are currently being explored as alternative methods for assessing
disease severity, response to therapy, and disease progression [3–5].
Dyspnea is one of the most common and disabling symptoms
in COPD [3,6,7]. It is frequently associated with decreases infunctional status, physical activity, and quality of life [8–10]. The
therapeutic goals for patients with COPD include relief from
symptoms such as dyspnea, improving health status, preventing
and treating exacerbations, slowing the progression of disease,
and reducing mortality [1,11]. Licensed indications for most
current COPD treatments are limited to improving airflow obstruc-
tion, and yet no US Food and Drug Administration (FDA)-approved
pharmacologic therapy currently has information on dyspnea in
its US label. As dyspnea is so important to the lives of patients
with COPD and it affects many of their daily activities, the
relationship between the two is important to properly evaluate.
The relationship between physical activity and breathlessness
in COPD is complex, and various models have been developed to
help facilitate an understanding of this association. Jolley and
Moxham [9] described a physiologic model of patient-reported
breathlessness based on the relationship between ventilatory
load, respiratory muscle capacity, neural respiratory drive, and
neuromechanical dissociation during daily activities. Conversely,for Pharmacoeconomics and Outcomes Research (ISPOR).
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patient-reported outcome (PRO) instrument development using
patient descriptions of dyspnea and functional limitations in COPD.
On the basis of qualitative research, Victorson’s group concluded
that five primary components make up the patient’s experience of
dyspnea: breathlessness, fatigue, activity modification, activity
limitation, and emotional response. Their model describes how
dyspnea symptoms impair function and are mediated by personal
and environmental factors. Both the physiologic and conceptual
models provided a structure on which to base Shortness of Breath
with Daily Activities (SOBDA) questionnaire development for mea-
suring the severity of breathlessness during daily activities. With
the understanding gained from these models, we attempted to
assess qualitative outcomes in COPD relating to dyspnea.
Qualitative studies are increasingly recognized to be as impor-
tant to our understanding of the patient experience of dyspnea as
studies focusing on other physical aspects of COPD. The results of
such studies explain, at least in part, why two people with the same
physiologic markers of COPD severity often experience and describe
different levels of dyspnea. To develop an instrument that accu-
rately captures how patients perceive dyspnea, a patient-centered
approach using their words to describe symptoms is necessary.
Such an instrument needs to be valid, reliable, and responsive to
change, meeting the criteria outlined in the FDA PRO Guidance
document [13], if the intent is to support a label claim for a
medicinal product in the United States. No instruments for asses-
sing COPD-related dyspnea have been qualified for the target
population to achieve an indication of a medicinal product by the
FDA for inclusion into product labels at the time of writing. We
developed the SOBDA questionnaire to assess the impact of daily
activities on dyspnea in patients with COPD. The goal of this phase
of development was to construct an instrument for assessing SOB
during patient-identified daily activities that is based on patient
feedback on specific terminology and patient experiences with SOB.Methods
The process for developing the SOBDA questionnaire involved
multiple steps and review processes. Focus groups of patients
with COPD were conducted in clinic offices and meeting rooms in
San Diego, CA, San Antonio, TX, New Brunswick, NJ, and Miami,
FL, and each session lasted for approximately 1.5 to 2 hours. The
moderator’s discussion guide for the focus groups was developed
on the basis of current relevant literature, learnings from pre-
vious models such as those developed by Jolley and Moxham [9]
and Victorson et al. [12], and input from clinical experts, and was
used to facilitate discussions on patients’ experiences of SOB
with daily activities. A pool of items was drafted on the basis of
information gathered from the focus groups and literature
reviews, and these items were then discussed among instrument
development and pulmonary experts. In addition, four transla-
tion experts and a lexibility expert reviewed the questionnaire to
ensure cross-cultural equivalence and translational feasibility, as
well as clarity of wording. Cognitive debriefing interviews of
patients were subsequently conducted to evaluate the draft item
pool, and feedback from these interviews was used to develop
newer versions of the questionnaire.
Patients
For both the focus group discussions (phase 1) and cognitive
debriefings (phase 2), efforts were made to recruit from pulmon-
ary clinics in the United States participants with a variety of
educational, sociodemographic, and ethnic backgrounds, as
well as diverse disease experiences. The demography and clinical
characteristics of the recruited participants were intentionallychosen to include and expand beyond that of a typical COPD
clinical trial population in order for the instrument to be able
to be used in a broader trial population. Economic diversity was
addressed by using zip codes as a surrogate for socioeconomic
status [14]. Clinics from across the United States were instructed
to enroll participants with different disease severities to achieve
the following target population: 15% Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stage I, 35% GOLD stage II, 35%
GOLD stage III, and 15% GOLD stage IV. The target number of desired
participants for this study was 40; however, the total number could
be modified on the basis of whether concept saturation (i.e., no new
concepts or information emerging from subsequent focus groups)
was reached [15–18]. Saturation was expected to be reached during
focus group discussions by approximately 30 patients. If saturation
was not reached, additional participants could be added. Protocols
were approved by an institutional review board, and patient consent
was obtained prior to the discussion of study-related materials.
Clinicians completed an enrollment form, confirming each patient’s
eligibility and disease severity.
Inclusion criteria were as follows: 40 to 80 years of age;
current or former smokers with a history of at least 10 pack-
years; current diagnosis of COPD and/or chronic bronchitis as
defined by the GOLD initiative [1]; willing and able to provide
written informed consent; able to participate in a group discus-
sion; and able to speak and read English.
Exclusion criteria were as follows: respiratory disorders other
than COPD (e.g., asthma); organic heart disease with resultant left
ventricular failure and New York Heart Association class II to IV;
clinically relevant bronchiectasis; recent COPD exacerbation
(within previous 60 days); neuromuscular disease; possible causes
of significant dyspnea/fatigue other than COPD, including severe
anemia; and concurrent medical or psychiatric condition or cog-
nitive impairment potentially affecting participation in the study.
Measures
Upon completion of both the focus group discussions and cognitive
debriefings, all patients completed a brief sociodemographic ques-
tionnaire that provided reviewers with additional information on
the patient population. In addition, patients were assessed by using
the following validated measures: the modified Medical Research
Council dyspnea scale [19], the St. George’s Respiratory Question-
naire for COPD patients [20,21], and the Chronic Respiratory Ques-
tionnaire – Self-Administered Standardized [22–24].
Focus Groups
Moderators used a standardized discussion guide to solicit
terminology used by patients to describe the sensation of dys-
pnea and to explore the circumstances in which participants
experienced the sensation. Patients were initially asked to ‘‘tell
me about your breathing,’’ which prompted them to explain their
experience with dyspnea and the differences in sensations of
dyspnea compared with chest congestion, chest tightness, and
wheezing. Patients were then asked to describe the general
activities they conducted on a daily basis, as well as their level
of dyspnea as they conducted these activities. Moderators probed
on specific dyspnea-inducing aspects of the activities, and
patients were asked to describe any body movements or posi-
tions that impact dyspnea. All discussion probes were phrased as
open-ended questions, using only the terminology that patients
provided. The verbatim terms that patients used to describe their
dyspnea were coded for the frequency of occurrence. As each
concept reached saturation, final sessions were focused on
supplementing missing information relating to activities, but an
open discussion of the other topics was still encouraged by the
moderators.
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Based on the literature review and results of the focus groups, a pool
of items was drafted and discussed among instrument development
and clinical experts. The draft pool was adjusted to improve
grammar and ensure cross-cultural equivalence and translational
feasibility according to standard cross-cultural translation and adap-
tion processes [25]. Response options were based on the focus group
results and modified to include feedback on all levels of dyspnea.
As the SOBDA questionnaire was intended to be completed
daily using an electronic format, the items were loaded onto a
LogPad personal digital assistant by PHT Corporation. Items and
responses too long to fit on the screen were adjusted; the
shortening of items and responses is a standard procedure when
transitioning from paper to an electronic format and did not
require significant changes to the wording of existing items [26].
A review by translation experts and a lexibility expert resulted in
Version 1.0 of the SOBDA questionnaire.
Cognitive Debriefing Interviews
Four rounds of one-to-one cognitive debriefing interviews were
conducted in San Antonio, TX, New Brunswick, NJ, and Topeka, KS.
An interview guide with structured and open-ended questions was
developed to optimize consistency. Probes were also used to under-
stand how patients interpreted wording in the questionnaire and
how they selected their response. The response options (slightly,
moderately, severely, and so severe that I could not do the activity)
were based on the commonly used Likert scale [27], and patients
were asked whether these options were meaningful in terms of their
own SOB experience. For each of the response options, patients were
asked to provide an activity causing them to experience that level of
SOB. Stick figures were used to demonstrate body positions asso-
ciated with various activities because of the impact certain positions
have on SOB. During each interview, patients were shown stick
figures in various positions and asked what activities they may
conduct in such positions. These figures were included as a referent
for the activity described in the text as well as to provide a starting
point from which activities could be culturally adapted during the
translation process. Although the activities could be altered on the
basis of cultural relevance, the body position represented by the stick
figures remained the same. The interview guide was updated after
each round of interviews, on the basis of patients’ comments.
During each round of cognitive interviews, the electronic
format of the SOBDA questionnaire was used. Version 1.0 of the
SOBDA questionnaire was used in the first two rounds of cognitive
debriefing interviews, and this was then refined on the basis of
participant feedback and suggestions. Version 1.1 was adminis-
tered during the third round of interviews, and further changes
were subsequently made. The resulting Version 1.2 was reviewed
internally by GlaxoSmithKline experts and updated, and Version
1.3 was submitted as part of a briefing package to the FDA. The
questionnaire was modified on the basis of FDA feedback, after
which Version 1.4 was developed and used during a fourth round
of interviews, conducted in Houston, TX, and Topeka, KS. Patients
were asked to ‘‘think aloud’’ when they read each question, and to
describe the time frame and factors they considered when select-
ing their response. Also, patients were asked whether they under-
stood the instructions and could explain them in their own words.
Data Analysis
Descriptive statistics (mean, SD, and frequency) were used to
characterize the focus group and cognitive debriefing samples
in terms of sociodemographic, health status, and clinical
characteristics.
Focus group data analysis focused on establishing content
validity of the information gathered [13] and was based onaudiotapes, notes taken by the moderator, and moderator recall
of the discussions. The evaluation included 1) generation of key
words, phrases, and quotes; 2) rating of these attributes by
importance (based on the frequency of which symptoms were
mentioned within and between focus groups); and 3) identifica-
tion of additional themes relevant to participants’ experiences. A
qualitative analysis software program, ATLAS.ti Version 5.0 [28],
facilitated the process. From the evaluation process, a prelimin-
ary coding dictionary was developed by a team composed of four
members, including two focus group moderators. Words and
phrases were selected and grouped into key themes, attributes,
concepts, and relationships. Subsequent revisions were made by
the team to refine the concepts and respective definitions.
Focus Group Saturation
The FDA guidance requires evidence of saturation to establish
content validity in the development of PRO instruments designed
for use as clinical trial end points [13]. The number of partici-
pants needed to reach saturation is largely driven by the com-
plexity of the concept and the diversity of the participants.
The qualitative data were examined following the focus
groups for specific issues and concerns associated with the
SOBDA questionnaire. Instrument revisions were considered on
the basis of cognitive debriefing interviews. Qualitative data from
the last round of interviews were compared with earlier data to
explore patients’ interpretation of the items, which enabled the
degree of saturation to be assessed.Results
Focus Group Discussions
Participant demography and clinical characteristics
Phase 1 (concept elicitation) consisted of seven focus group
discussions. A total of 40 patients participated in these focus
groups that were conducted in California, Texas, New Jersey, and
Florida over a 3-month period. Demographic and clinical char-
acteristics of the patients are provided in Table 1.
Emerging themes and concepts and patient description of
dyspnea
No differences were found in the descriptions of dyspnea, or
activities/experiences with dyspnea between genders or across
ethnic or socioeconomic backgrounds. Throughout all focus
groups, patients described a feeling of not being able to breathe
deeply enough to pull a sufficient amount of air into their lungs.
They felt that their lungs could not expand enough to get a full
breath of air and described the struggle they had in overcoming
the perceived restriction.
The terms ‘‘shortness of breath,’’ ‘‘difficulty breathing,’’
‘‘labored breathing,’’ ‘‘can’t breathe,’’ and ‘‘out of breath’’ were
frequently used to describe the sensation of dyspnea from COPD.
Among all ethnic groups, the expressions ‘‘short of breath’’ or
‘‘difficulty breathing’’ were used most often.
There was consistent distinction between SOB and chest con-
gestion, chest tightness, and wheezing. Chest congestion was
described as the sensation of having phlegm or mucus in the chest
or throat, with the need to expel or cough. When the moderator
probed further, patients reinforced that chest congestion was very
different from SOB. Patients often discussed chest tightness in
conjunction with SOB, but patients confirmed that these were two
different feelings. Most times, chest tightness was described as
being a precursor or an indicator that they would not be able to
take the next breath as easily. Wheezing was associated with the
sound of having phlegm or mucus stuck in the chest or throat.
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others were highly bothered by the noise. All patients emphatically
concluded that wheezing was different from being short of breath.
SOB with Activity
Patients provided a variety of activities in which they experienced
SOB. Throughout the group sessions, it became increasingly
evident that SOB with some activities had a greater association
with body position, as well as the level of exertion. Many patients
experienced an increased level of SOB simply by sitting down and
bending to tie their shoelaces. A number of body positions wereTable 1 – Demographic and clinical characteristics.
Characteristics Focus group
participants (n ¼ 4
Age (y), mean 7 SD 66.0 7 9.0
Gender, n (%)
Male 16 (40.0)
Race, n (%)*
White 25 (62.5)
Black/African American 7 (17.5)
Hispanic or Latino 5 (12.5)
Asian 1 (2.5)
Other 2 (5.0)
Employment, n (%)*
Full-time/part-time 12 (30)
Retired 20 (50.0)
Disabled 7 (17.5)
Other 3 (7.5)
Education, n (%)
High school or less 23 (57.5)
Associate degree/
technical/
trade school
6 (15.0)
College 6 (15.0)
Graduate degree 2 (5.0)
Other 3 (7.5)
GOLD stage, n (%)
I 3 (7.5)
II 13 (32.5)
III 21 (52.5)
IV 3 (7.5)
Pulmonary function,
mean 7 SD
FEV1 (L) 1.3 7 0.6†
FEV1 (% predicted) 51.4 7 19.9†
FVC (L) 2.3 7 0.8†
mMRC, mean 7 SD 3.0 7 1.0
Clinician-rated mMRC, n (%)
No breathlessness 3 (7.5)
Breathlessness when
hurrying
9 (22.5)
Walks slower than people of
the same age
10 (25.0)
Stop for breath 15 (37.5)
Too breathless 0 (0)
Did not respond 3 (7.5)
SGRQ-C
Total, mean 7 SD 52.4 7 20.1
Symptom, mean 7 SD 63.7 7 21.3
Activity, mean 7 SD 64.5 7 24.3
Impact, mean 7 SD 40.9 7 22.7identified in which patients experienced SOB; patients were
asked to identify activities they might do in those positions.
Fig. 1 includes a symptom model from the patient perspective.
This disease model demonstrates the link between the SOBDA
questionnaire items and the pathophysiologic factors associated
with SOB. Table 2 provides patients’ descriptions of SOB and SOB-
related limitations.
Focus Group Saturation
Table 3 presents evidence that saturation of the various compo-
nents of dyspnea described was met through the seven focus0)
Cognitive debriefing
participants (n ¼ 37)
Qualitative research
total sample (n ¼ 77)
61.1 7 11.8 63.67 10.6
20 (54.1) 36 (46.8)
22 (59.5) 47 (61.0)
3 (8.1) 10 (13.0)
5 (13.5) 10 (13.0)
7 (18.9) 8 (10.4)
1 (2.7) 3 (3.9)
16 (43.2) 28 (36.4)
16 (43.2) 36 (46.8)
7 (18.9) 14 (18.2)
2 (5.4) 5 (6.5)
22 (59.5) 45 (58.5)
7 (18.9) 13 (16.9)
5 (13.5) 11 (14.3)
3 (8.1) 5 (6.5)
0 (0) 3 (3.9)
10 (27.0) 13 (16.9)
11 (29.7) 24 (31.2)
8 (21.6) 29 (37.7)
8 (21.6) 11 (14.3)
1.87 0.8 1.67 0.8z
61.5 7 24.1 56.57 22.5z
3.07 1.1 2.77 1.0z
2.87 0.9 2.97 0.9I¨
1 (2.7) 4 (5.2)
15 (40.5) 24 (31.2)
12 (32.4) 22 (28.6)
9 (24.3) 24 (31.2)
0 (0) 0 (0)
0 (0) 3 (3.8)
51.0 7 19.1J 51.77 19.5z
55.4 7 32.0 59.77 27.1
65.3 7 24.6† 64.97 24.3#
39.3 7 20.2† 40.17 21.5#
(Continued on next page)
Table 1 (continued)
Characteristics Focus group
participants (n ¼ 40)
Cognitive debriefing
participants (n ¼ 37)
Qualitative research
total sample (n ¼ 77)
CRQ-SAS
Dyspnea, mean 7 SD 4.6 7 1.6 5.07 1.5** 4.87 1.5z
Fatigue, mean 7 SD 4.1 7 1.1 4.27 1.3†† 4.17 1.2I¨
Emotional, mean 7 SD 4.5 7 1.0 4.67 0.9†† 4.57 1.0I¨
Mastery, mean 7 SD 4.0 7 0.8 4.57 1.0†† 4.27 0.9I¨
Smoking Status
Current smoker, n (%) 10 (25.0) 14 (37.8) 24 (31.2)
Ex-smoker, n (%) 28 (70.0) 23 (62.2) 51 (66.2)
Did not respond 2 (5.0) 0 (0) 2 (2.6)
Current smoker (y), mean 7 SD 36.0 7 16.7 29.0 7 17.6 31.97 17.2
Ex-smoker—years smoked, mean 7 SD 33.4 7 10.7 34.8 7 11.2zz 34.07 10.8I¨I¨
COPD, chronic obstructive pulmonary disease; CRQ-SAS, Chronic Respiratory Questionnaire – Self-Administered Standardized; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical
Research Council; SGRQ-C, St. George’s Respiratory Questionnaire for COPD patients.
* Not mutually exclusive.
† n ¼ 36.
z n ¼ 73.
I¨ n ¼ 74.
J n ¼ 35.
z n ¼ 75.
# n ¼ 76.
** n ¼ 33.
†† n ¼ 34.
zz n ¼ 22.
I¨I¨ n ¼ 49.
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terminology that patients use to describe dyspnea (‘‘short of
breath,’’ ‘‘can’t catch breath,’’ and ‘‘trouble breathing’’), body
positions (e.g., bending or reaching), and activities when patients
experience dyspnea (showering, dressing, housework, exercise,
etc.). It was therefore determined that additional focus groups
were not necessary. Spontaneous versus probed tallies were not
made during the focus groups as concepts were spontaneous
only for the first time one patient mentions a concept; it is probed
thereafter because the concept is already known to patients and
they no longer have the opportunity to be spontaneous.
Item Pool Development
Item wording
Key words used by the patients (e.g., ‘‘short of breath’’ and
‘‘dressing’’) were instrumental in the development of each item.
The importance of key words was determined on the basis of the
frequency with which a particular word was used. Body positions
of the stick figure illustrations were described by the patients and
entered into a grid, followed by activities identified by the patientsFig. 1 – Symptom model from a patient’s perspective. * During th
SOB from congestion and wheezing.for each body position. Response options were also chosen on the
basis of patient descriptions of SOB severity from the focus group
sessions, including ‘‘did not do’’ to account for adaptation by the
patient. Some patients stated that they had difficulty interpreting
what ‘‘I did not do’’ meant to them. To clarify the meaning of this
response option, ‘‘I did not do’’ was changed to ‘‘I did not do the
activity today.’’ In addition, some activities may or may not be
performed because of gender; however, the majority of patients
stated that their gender did not impact whether they performed
the activities listed on the questionnaire.Cognitive Debriefing Discussions
Patient demography and clinical characteristics
Phase 2 consisted of cognitive debriefing interviews. A total of 37
patients participated in these interviews over a 3-month period:
10 patients participated in the first round, 10 patients in the
second round, 5 patients in the third round, and 12 patients in
the fourth round. The patients’ demographic and clinical char-
acteristics are provided in Table 1.e focus group discussions, patients were able to distinguish
Table 2 – Patient descriptions of dyspnea (shortness of
breath).
Description of shortness of breath
‘‘Well, it’s like breathing inside a box or something. It’s just kind
of a restricted feeling. It’s uncomfortable. It’s restricting.’’
‘‘You can’t catch your breath.’’
‘‘Without air.’’
‘‘Struggling for breath.’’
‘‘Breath gets a little short.’’
‘‘I can’t expand my lungs. I can’t pull in enough air.’’
‘‘Gasping.’’
‘‘You can’t get enough air or oxygen, or whatever the hell it is, to
catch your breath.’’
‘‘Like a struggle for a deep breath. It’s like struggling for breath.’’
‘‘Because really shortness of breath is struggling to take that
deep breath. It’s like breathing shallowly as opposed to
breathing deeply. I guess I normally would breathe shallowly,
and then when sometimes you want to take a deep breath
and you just can’t get it.’’
‘‘It’s like you’ve got a wet towel over your face.’’
‘‘Well, you suffocate—it’s absolutely suffocating.’’
Description of shortness of breath with activities
‘‘On the floor and I’m picking stuff up.’’
‘‘It could be sweeping.’’
‘‘Vacuuming and moving furniture around.’’ ‘‘Like cleaning
house or something like that, vacuuming is my worst and
when I wash windows. But I’m an up-and-down, bending-
over type of window washer.’’
‘‘I have a chair in my shower. I can’t stand up and do this to my
hair.’’
‘‘I’ve gotten breathless in the shower a couple times, and I just
now have realized why. And it is, it’s the bending over to
shave my legs. That’s what it is, and I had not related
anything to bending over.’’
Adaptation
‘‘I used to belong to the gym, and I don’t even attempt to do that
anymore. Because I really liked the walking and the treadmill
and the weights. You’re allowed so much time on the
weights, but people are waiting. If it’s going to take you twice
as long to use the weights than someone else, people are
going to get impatient.’’
‘‘I don’t do too much reaching because I organized everything in
my house that it’s probably just as high as I have to goy..
Because I organize things so I don’t have to stretch or do
things.’’
‘‘I cannot talk while I’m going up the stairs. If people want you to
‘‘talk’’ as you’re walking along and going up stairs, I can’t do
both. I can do one or the other.’’
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Each interview lasted 1.5 to 2 hours. Overall, the SOBDA question-
naire was well received: patients confirmed that the questionnaire
was clear and easy to understand and captured most daily activities.
Patients reported that the items were, in general, relevant to their
experiences with breathing problems while performing their daily
activities. However, those with more severe COPD found some of the
items to be less relevant because they were not able to do the
activities. In addition, patients were asked whether their gender
affected their likelihood of undertaking activities on the question-
naire; the majority said ‘‘no.’’
The SOBDA questionnaire is intended to be used as a daily
diary. However, several interviews were conducted in the morn-
ing, which made it difficult for patients to think about theirexperiences ‘‘today’’ because it was early. A few patients stated
that they thought of a ‘‘typical day’’ or ‘‘yesterday’’ when complet-
ing the questions. The patients stated that the instructions and
response options on the questionnaire made it very clear that the
time frame is ‘‘today,’’ meaning the period of time from when they
woke up until they went to bed and that patients should complete
the questionnaire before they go to bed at the end of the day.
Fourth Round of Cognitive Debriefing Interviews
Following consultation with the FDA, feedback was received
stating that illustrating an activity with a specific body position
might imply a requirement to perform the activity in that
position, while in practice there is variation (e.g., some partici-
pants may brush their teeth while standing up instead of bending
over the sink). Consequently, the stick figure illustrations were
removed to avoid the risk of confusion or nonresponse (‘‘did not
do the activity today’’). The response options and instructions
were also modified on the basis of FDA feedback.
The resulting version (Version 1.4) was presented to patients
in the fourth round of cognitive debriefing interviews. Partici-
pants with less severe COPD found some items to be less relevant
to their SOB experiences, but the range of items successfully
ensured applicability across a wide range of patients. Patients
using Version 1.4 reported that the instructions were clear and
easy to understand. Their explanations of what the instructions
and time frame meant were appropriate and indicated correct
interpretation.
Electronic Format User Acceptability
During all the cognitive debriefing interviews, patients were
briefly instructed on how to use the electronic questionnaire,
and then asked to answer SOBDA questionnaire items by using a
personal digital assistant. During the first three rounds of inter-
views, participants reported that the electronic format was easy
to use and that they would not have a problem using the device
in a study. In the fourth round, patients who commented on the
use of the personal digital assistant did not report any difficulty.Discussion
In developing an instrument to assess disease symptoms from the
patient perspective, the use of patient-based terminology is critical.
The SOBDA questionnaire was developed by using a patient-
centered approach to the terminology and structure, and patients
considered the resulting questionnaire to be clear and easy to
understand. In addition, in order to account for possible issues
regarding translatability and cultural differences, four translation
experts and one lexibility expert reviewed the conceptual model and
provided feedback on its relevance in specific countries and at the
global level and on the overall translatability of the instrument. In
accordance with standard cross-cultural translation and adaption
processes, adjustments were made throughout the development of
the SOBDA questionnaire to create an instrument with items that
were understandable across cultures, at the appropriate reading
grade level for all patients, particularly in areas of limited health
literacy, and that could be utilized in clinical trials worldwide [25].
Patients with COPD usually use the term ‘‘shortness of breath’’ to
describe their dyspnea [29–36]. Patients with COPD perceive SOB
as one of the major symptoms impairing their quality of life and
well-being. Ho et al. [8] reported that patients experiencing dyspnea
scored significantly lower in all four domains (mobility, kitchen,
domestic and leisure activities) of the Nottingham Extended Activ-
ities of Daily Living index than do those not experiencing dyspnea
[37]. Mobility tasks were affected to the greatest extent. There was
also a significant difference in total Hospital Anxiety and Depression
Table 3 – FG saturation grid.
FG1
(n ¼ 8)
FG2
(n ¼ 9)
FG3
(n ¼ 5)
FG4
(n ¼ 4)
FG5
(n ¼ 7)
FG6
(n ¼ 4)
FG7
(n ¼ 5)
Dyspnea terms
SOB O O O O O O O
Can’t catch breath O O O O O O
Trouble breathing O O O O
Labored breathing O O O O O O
Activity
Showering O O O O
Dressing O O O
Brushing teeth O O
Grooming O O O *
Tying shoelaces, pantyhose, and
socks
O O O O *
Vacuuming O O O
Housework/ cleaning O O O O O O
Grocery shopping O O O O O *
Getting mail
Sex O O
Walking on level O O O O O O O
Walking on incline O O O O O O
Swimming O O O O
Biking O O
Gardening/yard work O O O O O O O
Talking O O *
Laughing O
Dancing O O
Carrying heavy objects O O O
FG, focus group; SOB, shortness of breath.
* Participants noted as affecting their breathing only after being prompted by the moderator. FG, focus group; SOB, shortness of breath.
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suggesting that breathing problems are associated with anxiety and
depression [37–41]. Patients have described dyspnea as being ‘‘hard
work’’ [42], ‘‘a constant struggle’’ [43,44], ‘‘a continuous fight’’ [45],
‘‘painful,’’ ‘‘taking all one’s strength,’’ and ‘‘exhausting’’ [44].
Study participants often find it difficult to convey their perso-
nal experience of dyspnea to others. Nicholls [44] observed that
patients may instead describe dyspnea by creating mental pic-
tures: ‘‘a dark cloud,’’ ‘‘a battle,’’ ‘‘a wall,’’ or metaphorically,
describing that ‘‘life was closing in’’ or that they needed to ‘‘steer
a careful course’’ if dyspnea was unpredictable. However, such
descriptions are difficult to quantify, necessitating the use of other
measures to capture patient experiences. Previously developed
PRO questionnaires do not adequately address the dyspnea com-
ponent of COPD or meet FDA standards for instrument develop-
ment. For example, the St. George’s Respiratory Questionnaire for
COPD patients and other measures such as Chronic Respiratory
Questionnaire – Self-Administered Standardized (although well
used) have not undergone rigorous study in terms of content
validity and ability to reflect patient voice. The FDA requires
content validity and saturation of data to be demonstrated for
PROs in order for the data to support labeling and promotional
claims [13].
In line with FDA guidance, this research was designed to
gather qualitative evidence to inform the development of a new
PRO instrument, with a focus on measuring the effect of dyspnea
on the daily activities of patients with COPD. An important
component of qualitative research is establishing content valid-
ity. Content validity is the extent to which the content of an
instrument represents the most important aspects of a given
concept [46]. In the FDA guidance on PRO measurement, contentvalidity is defined as evidence that the items and domains of an
instrument are appropriate and are comprehensive relative to its
intended measurement concept, population, and use [13]. Such
evidence includes documentation from qualitative research,
which demonstrates that the PRO instrument measures the
concept of interest. In addition, qualitative patient data are
essential for establishing content validity of a PRO instrument.
Content validity is essential for the interpretability of the concept
measured. Qualitative data in the current evaluation were col-
lected through focus groups with patients with COPD, reviewed
by experts in pulmonary research to assess content validity from
a clinical perspective, reviewed by translation experts to mini-
mize potential translation difficulties and cross-cultural differ-
ences, and discussed during cognitive debriefing interviews
with patients to ensure that the draft instrument remained
understandable and relevant. The usability of the SOBDA ques-
tionnaire on an electronic device was also assessed. The exten-
sive involvement of patients with characteristics typical of those
with COPD ensured that the questionnaire effectively reflects
patients’ own perspectives.
This article highlights the most important issues and ideas
that came out of the focus groups. The terminology used by
patients to describe the sensation of dyspnea (SOB), and the
varying degrees of SOB associated with everyday activities and
hobbies, was the primary focus of discussion. Patients were able
to distinguish SOB from chest congestion, wheezing, and chest
tightness, and most often described their experience with terms
such as ‘‘short of breath’’ and ‘‘difficulty breathing.’’
Focus group transcripts were central to the development of the
item pool. Items were derived from patient comments and
experiences related to everyday activities. Stick figure illustrations
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 4 2 – 1 0 5 0 1049were initially included within the instrument because of the
reported impact of body position on SOB. The illustrations were
later removed from the questionnaire following feedback received
from the FDA. It is anticipated, however, that they will be useful
during the process of translating the questionnaire as they provide
additional information to ensure cross-cultural equivalence.
The qualitative data obtained during the cognitive debriefing
interviews were used to confirm the content validity of items
selected for the SOBDA questionnaire. Overall, descriptions of
dyspnea did not vary across the GOLD stages. The activities listed
in the questionnaire represented everyday experiences for GOLD
stage I to GOLD stage IV patients, although GOLD stage I patients
reported SOB difficulty only when doing physically demanding
activities. The questions were designed to measure dyspnea
associated with daily activities across a wide range of disease
severity to ensure suitability of the SOBDA questionnaire for all
patients with COPD.Conclusions
Qualitative research with patients with COPD was the basis for
developing the SOBDA questionnaire. Patients included in the
research had the full range of COPD severity and a wide spread
across both socioeconomic status and ethnicity. Concept satura-
tion was reached during patient focus groups. Comments from
the FDA were carefully considered, and appropriate revisions
were made. The item pool contains 37 items to assess SOB
associated with everyday activities. Instructions and response
options were well understood by patients with COPD, and the
items’ relevance was confirmed. Scoring, scaling, reliability,
validity, and responsiveness will be assessed in future prospec-
tive validation studies.Acknowledgments
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